Filing Flows › OptimizeRx (OPRX) › Q2 2026 › vs Q2 2025
OptimizeRx (OPRX) Q2 2026 vs Q2 2025 (year over year)
OptimizeRx's revenue fell $8.7M (-30%) from $29.2M in Q2 2025 to $20.5M in Q2 2026.
OptimizeRx, Q2 2026: revenue $20.5M (-30% year over year), operating margin -0.4%, net loss $703K, operating cash flow $8.6M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 41.8% | 15.6% | +26.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $20.5M | $29.2M | −$8.7M | -30% |
| Income tax benefit | $393K | −$199K | $592K | — |
| Net loss | $703K | −$1.5M | $2.2M | — |
| Costs & expenses | $21.6M | $29.2M | −$7.6M | -26% |
| Operating costs | $20.6M | $26.0M | −$5.4M | -21% |
| Interest & other, net | $1.0M | $1.5M | −$468K | -32% |
| Research & development | $3.3M | $3.1M | $182K | +6% |
| Sales & marketing | $5.5M | $5.9M | −$337K | -6% |
| General & admin | $3.7M | $3.9M | −$207K | -5% |
| Other operating costs | $3.3M | $2.6M | $710K | +28% |
| Operating cash sources | $9.3M | $3.0M | $6.3M | +207% |
| Depreciation & amortization | $1.1M | $1.1M | −$10K | -0.9% |
| Share-based compensation | $2.2M | $1.5M | $720K | +48% |
| Working capital & other | $6.0M | $467K | $5.6M | 13× |
| Net loss absorbed | $703K | −$1.5M | $2.2M | — |
| Operating cash flow | $8.6M | $4.6M | $4.0M | +89% |
| Free cash flow (OCF − capex) | $8.6M | $4.6M | $4.0M | +88% |
| Capital expenditures | $35K | $10K | $25K | +250% |
Questions
How much did OptimizeRx's revenue grow year over year in Q2 2026?
OptimizeRx's revenue fell $8.7M (-30%) from $29.2M in Q2 2025 to $20.5M in Q2 2026.